Alector (ALEC) Shares Outstanding (Diluted Average) (2020 - 2026)
Alector (ALEC) reported Shares Outstanding (Diluted Average) of $110.6 million for Q1 2026, up 11.26% year-over-year from $99.4 million in Q1 2025, and up 7.37% quarter-over-quarter from $103.0 million in Q4 2025.
Alector (ALEC) Shares Outstanding (Diluted Average) (2020 - 2026) Analysis & Trends
Alector (ALEC) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $110.6 million in Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $110.6 million, up 11.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $110.6 million (up 11.26% YoY), and the FY2025 annual result was $103.0 million, up 6.64% from the prior year.
- Shares Outstanding (Diluted Average) climbed to $110.6 million in Q1 2026 per ALEC's latest filing, from $103.0 million in the prior quarter.
- Over five years, Shares Outstanding (Diluted Average) peaked at $110.6 million in Q1 2026 and troughed at $82.1 million in Q1 2022.
- A 5-year average of $92.3 million and a median of $94.5 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Diluted Average) gained 1.22% in 2023, then increased 15.35% in 2024.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $82.5 million in 2022, then advanced by 1.54% to $83.7 million in 2023, then increased by 15.35% to $96.6 million in 2024, then grew by 6.64% to $103.0 million in 2025, then grew by 7.37% to $110.6 million in 2026.
- Business Quant data shows ALEC's Shares Outstanding (Diluted Average) at $110.6 million in Q1 2026, $103.0 million in Q4 2025, and $100.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Alector | 193.53 Mn | -12.98 Mn | - | 110.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 110.59 Mn |
| Dec 31, 2025 | 103.00 Mn |
| Sep 30, 2025 | 100.80 Mn |
| Jun 30, 2025 | 99.89 Mn |
| Mar 31, 2025 | 99.40 Mn |
| Dec 31, 2024 | 96.59 Mn |
| Sep 30, 2024 | 96.01 Mn |
| Jun 30, 2024 | 95.24 Mn |
| Mar 31, 2024 | 93.81 Mn |
| Dec 31, 2023 | 83.73 Mn |
| Sep 30, 2023 | 83.93 Mn |
| Jun 30, 2023 | 83.57 Mn |
| Mar 31, 2023 | 83.10 Mn |
| Dec 31, 2022 | 82.47 Mn |
| Sep 30, 2022 | 82.37 Mn |
| Mar 31, 2022 | 82.10 Mn |
| Dec 31, 2021 | 80.42 Mn |
| Dec 31, 2020 | 77.76 Mn |